¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"time factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • competence factor
    1. ¸é¿ª°¡´ÉÀÎÀÚ 2. ¹ÝÀÀ°¡´ÉÀÎÀÚ
  • competence inducing factor
    ¸é¿ª°¡´ÉÀ¯¹ßÀÎÀÚ
  • complementary factor
    º¸ÃæÀÎÀÚ
  • conglutinogen activating factor
    ±³Âø¿øÈ°¼ºÀÎÀÚ
  • conversion factor
    º¯È¯ÀÎÀÚ, º¯È¯°è¼ö
  • carcinogenic factor
    ¹ß¾ÏÀÎÀÚ
  • corticotropin-releasing factor
    ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó¹æÃâÀÎÀÚ
  • chemotactic factor
    È­Çнò¸²ÀÎÀÚ
  • drug resistance factor
    ¾àÁ¦ÀúÇ×ÀÎÀÚ
  • dermonecrotic factor
    ÇǺα«»çÀÎÀÚ
  • diabetogenic factor
    ´ç´¢º´À¯¹ßÀÎÀÚ
  • decay accelerating factor
    ºØ±«ÃËÁøÀÎÀÚ
  • dilution factor
    Èñ¼®ÀÎÀÚ
  • exclusion of confounding factor
    ±³¶õ¹èÁ¦ÀÎÀÚ
  • exogenous factor
    ¿ÜÀοä¼Ò
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • utilization time
    ÀÌ¿ë½Ã°£
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
  • voiding time
    ¹è´¢½Ã°£
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • alveolar dilution factor
    ÆóÆ÷Èñ¼®ÀÎÀÚ, ÇãÆÄ²Ê¸®Èñ¼®ÀÎÀÚ
  • amplification factor
    ÁõÆøÀÎÀÚ
  • antihemophlic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰ÀÎÀÚ
  • antipellagra factor
    Çׯç¶ó±×¶óÀÎÀÚ
  • antiphagocytic factor
    Çׯ÷½ÄÀÛ¿ëÀÎÀÚ
  • antirachitic factor
    Ç×±¸·íº´ÀÎÀÚ
  • antiscorbutic factor
    Ç×±«Ç÷º´ÀÎÀÚ
  • antisterility factor
    Ç׺ÒÀÓÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ³ªÆ®·ýÀÌ´¢ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • Growth factor
    ¼ºÀåÀÎÀÚ(à÷íþì×í­)
  • Hageman factor
    ÇϰԸ¸ÀÎÀÚ
  • Hydrostatic factor
    Á¤¼öÀÎÀÚ(ð¡â©ì×í­)
  • IGF-I(insulin-like growth factor-I)
    Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ-1
  • Luteinization -inhibiting factor
    Ȳüȭ¾ïÁ¦¿äÀÎ(üÜô÷ûùåäð¤é©ì×)
  • Macrophage colony-stimulating factor
    ´ë½Ä¼¼Æ÷Áý¶ôÇü¼ºÃËÁøÀÎÀÚ(ÓÞãÝá¬øàó¢Õªû¡à÷õµòäì×í­)à÷õµòäì×?
  • NGF=>nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • PAF =platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ.
  • PAF= platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼ºÀÎÀÚ.
  • Q factor
    Å¥ ÀÎÀÚ
  • Q-factor
    Å¥-ÀÎÀÚ (ì×í­)
  • R factor
    ³»¼ºÀÎÀÚ.
  • R factor
    ³»¼ºÀÎÀÚ.
  • Rh factor
    RhÀÎÀÚ.
  • Stuart-Prower factor
    ½ºÆ©¾îÆ®-ÇÁ¶ó¿ö ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • partial thromboplastin time=PTT
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£(õÌÍÔÒØöôãÁÊà).
  • perception time
    Áö°¢½Ã°£, ÀνĽð£.
  • persistence time
    Áö¼Ó½Ã°£(ò¥áÙãÁÊà).
  • phonation time
    ¹ß¼ºÁö¼Ó½Ã°£
  • plasma prothrombin time
    Ç÷ÀåÇÁ·ÎÆ®·Òºó ½Ã°£.
  • polymerizing time
    ±»´Â ½Ã°£ (ÁßÇÕ ½Ã°£)
  • potential doubling time (Tpot)
    ÀáÀç¹è°¡½Ã°£
  • potential tumor doubling time
    ÀáÀçÁ¾¾ç¹è°¡½Ã°£
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£.
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó ½Ã°£
  • prothromhin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • pulmonary circulation time
    Æó¼øÈ¯½Ã°£(¡­ãÁÊà).
  • reaction time
    ¹ÝÀÀ½Ã°£
  • reaction time
    ¹ÝÀÀ½Ã(°£)(ÚãëëãÁÊà).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • factor XII
    ÀÎÀÚ(ì×í­) XII
  • factor XIII
    ÀÎÀÚ(ì×í­) XIII
  • factor XIV
    ÀÎÀÚ(ì×í­) XIV
  • factor F
    ÀÎÀÚ(ì×í­) F
  • factor G
    ÀÎÀÚ(ì×í­) G
  • factor IF
    ÀÎÀÚ(ì×í­) IF
  • factor R
    ÀÎÀÚ(ì×í­) R
  • factor T
    ÀÎÀÚ(ì×í­) T
  • factor theory
    ÀÎÀÚ ÀÌ·Ð(ì×í­×âÖå)
  • factor X
    ÀÎÀÚ(ì×í­) X
  • factor Y
    ÀÎÀÚ(ì×í­) Y
  • fertility factor
    ¼öÁ¤ ÀÎÀÚ (áôïñì×í­)
  • F factor
    F ÀÎÀÚ(ì×í­)
  • F' factor
    F' ÀÎÀÚ(ì×í­)
  • fibrin-stabilizing factor
    ¼¶À¯¼Ò ¾ÈÁ¤È­ÀÎÀÚ(àéë«áÈäÌïÒûùì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
HF Hageman factor; haplotype frequency; hard filled [capsule]; hay fever; head of fetus; head forward; ...
IF idiopathic fibroplasia; idiopathic flushing; immersion foot; immunofluorescence; indirect fluorescen...
KAF conglutinogen-activating factor; killer-assisting factor; kinase activating factor
LEF leukokinesis-enhancing factor; lupus erythematosus factor; lymphoid-enhanced binding factor
LIF laser-induced fluorescence; left iliac fossa; left index finger; leukemia-inhibiting factor; leukocy...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
CRT Choice Reaction Time
CT Circadian Time
CIT Cold ischemic time
CTT Colonic transit time
C.t' Concentration-time
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • conversion factor
    º¯È¯ °è¼ö
  • cooperative factor
    Çùµ¿ ÀÎÀÚ
  • coronary risk factor
    °ü»ó µ¿¸Æ Áúȯ À§Çè ¿äÀÎ
  • cothromboplastin factor VII
    ÄÚÆ®·Ò º¸ÇÃ¶ó½ºÆ¾
  • coupling factor
    ¹è¿ì ÀÎÀÚ
  • covering factor
    ÇǺ¹ ÀÎÀÚ
  • cultural and ethnic factor
    ¹®È­ ¹ÎÁ·Àû ¿äÀÎ
  • cytotoxic factor
    ¼¼Æ÷ µ¶¼º ÀÎÀÚ
  • D and C ÀÚ±ÃÀÇ °æºÎ È®Àå°ú ³»¸· ¼ÒÆÄ.

    D factor

    D-ÀÎÀÚ
  • Decay accelerating factor
    ºØ±« °¡¼Ó ¿ä¼Ò
  • diabetogenic factor
    ´ç´¢ À¯¹ß ÀÎÀÚ
  • differentiation factor
    °¨º° ¿äÀÎ, °¨º° ¿ä¼Ò, °¨º° ÀÎÀÚ
  • diffusion factor
    È®»ê ÀÎÀÚ
  • dilution factor
    Èñ¼® ÀÎÀÚ
  • dose modifying factor
    ¼±·® ¼ö½Ä °è¼ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
antipernicious anaemia factor <biochemistry> Member of the water soluble B vitamin group, important in the proper function of the nervous system and important in proper carbohydrate, protein and fat metabolism.
(27 Sep 1997)
antisterility factor <biochemistry> Functions as an antioxidant, binds oxygen free radicals that can cause tissue damage, may also play a protective role in the coronary arteries from the damaging effects of cholesterol.
(27 Sep 1997)
antitermination factor <molecular biology> A gene regulatory protein that blocks signals for the transcription process to stop as a form of regulatory control over whatever the gene being transcribed is coding for.
(13 Jan 1998)
atrial natriuretic factor <chemical> A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight peptides derived from a common precursor and secreted by the heart atria. All these peptides share a sequence of about 20 amino acids.
Chemical name: Atriopeptin
(12 Dec 1998)
attenuation factor <radiobiology> A measure of the opacity of a layer of material for radiation transversing it, the ratio of the incident intensity to the transmitted intensity. It is equal to Io/I, where Io and I are the intensities of the incident and emergent radiation, respectively. In the usual sense of exponential absorption (I = Ioe- m x), the attenuation factor is e- m x, where x is the thickness of the material and m is the absorption coefficient.
(16 Dec 1997)
autocrine motility factor A member of the class of cytokines secreted by tumour cells. It elicits increases in cell motility and phosphoinositide metabolism in the secreting or producing cell via a pertussis toxin-sensitive g-protein signal transduction pathway. The factor has also been used as a marker for bladder cancer.
(12 Dec 1998)
B-cell differentiating factor <cytokine> A soluble cytokine factor produced by activated T-lymphocytes that promotes antibody production by causing proliferation and differentiation of B-cells.
Interleukin-4 induces the expression of class II major histocompatibility complex and fc receptors on B-cells. It also acts on T-lymphocytes, mast cell lines, and several other haematopoietic lineage cells including granulocyte, megakaryocyte, and erythroid precursors, as well as macrophages.
Acronym: IL-4
(12 Dec 1998)
B-cell stimulatory factor 2 <cytokine> A cytokine that stimulates the growth and differentiation of human B-cells and is also a growth factor for hybridomas and plasmacytomas.
It is produced by many different cells including T-cells, monocytes, and fibroblasts. A single chain 25 kD cytokine originally described as a pre B-cell growth factor, now known to have effects on a number of other cells including T-cells which are also stimulated to proliferate.
An inducer of acute phase proteins and a colony-stimulating factor acting on mouse bone marrow.
Acronym: IL-6
(12 Dec 1998)
bifidus factor An unidentified substance associated with Lactobacillus bifidus subsp. Pennsylvanicus, present in mammalian milk.
(05 Mar 2000)
bioaccumulation factor Concentration of a chemical in living tissue divided by its concentration in the animal's diet.
(09 Oct 1997)
bioconcentration factor Concentration of a chemical in an organism divided by its concentration in the test solution or environment (for example, concentration in fish divided by concentration in water).
(09 Oct 1997)
Bittner's milk factor Member of the retrovirus subfamily Oncornavirinae, antigenically distinct from the murine leukaemia-sarcoma complex, that is associated with adenocarcinomatous tumours of the mammary gland, commonly latent in wild and laboratory mice and causing cancer only in genetically susceptible strains under certain hormonal influences.
Synonym: Bittner agent, Bittner virus, Bittner's milk factor, mammary cancer virus of mice, milk factor, mouse mammary tumour virus.
(05 Mar 2000)
blood clotting factor <haematology> Any of a number of different protein factors which, when acting together, can form a blood clot shortly after platelets have broken at the site of the wound.
The factors have Roman numeral names, like VII, VIII, IX, X, XI, and XIII. Defects in the genes which code for any of these factors result in genetic diseases like haemophilia, which results from a defect in the gene for factor VIII or IX.
(09 Oct 1997)
blood coagulation factor inhibitors Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.
(12 Dec 1998)
brain-derived growth factor <growth factor> Small basic protein purified from pig brain, a member of the family of neurotrophic factors that also includes Nerve Growth Factor and neurotrophin 3.
In contrast to nerve growth factor, brain-derived neurotrophic factor is predominanantly (though not exclusively) localised in the CNS. It supports the survival of primary sensory neurons originating from the neural crest and ectodermal placodes that are not responsive to NGF.
In the brain brain-derived neurotrophic factor has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons.
Acronym: BDGF
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • mountain time
    »êÁö Ç¥ÁؽÃ
  • needle time
    (¿µ)(¹æ¼Û)·¹ÄÚµå À½¾Ç½Ã°£
  • oneline real time system
    Á÷°á ½Ç½Ã°£ ó¸® ¹æ½Ä
  • part time
    Á¤»ó(±Ù¹«)½Ã°£ÀÇ ÀϺÎ
  • post time
    ¿ìÆí ¹ß¼Û ½Ã°£;¿ìÆí Áý¹è ½Ã°£;·¹À̽º ÃâÀü ¿¹Á¤ ½Ã°£
  • prime time
    (¶óµð¿À,ÅÚ·¹ºñÀüÀÇ)°ñµç ¾Æ¿ö
  • pulse time modulation
    ÆÞ½º½Ã º¯Á¶
  • question time
    Áú¹® ½Ã°£
  • quick time
    ¼Óº¸;1½Ã°£ 4¸¶ÀÏ
  • ragged time
    (³ëÁ£±â µîÀÌ)°í¸£Áö ¾ÊÀ½
  • reaction time
    ¹ÝÀÀ ½Ã°£
  • real time
    ½Ç½Ã°£;Áï½Ã ÀÀ´ä(»ç»ó°ú ±× µ¥ÀÌÅÍ Ã³¸®°¡ °°Àº ¼Óµµ·Î 󸮵Ê);Áï½Ã;µ¿½Ã
  • real-time
    ½Ç½Ã°£ÀÇ;(±â·Ï.¹æ¼ÛµîÀÌ)Áï½ÃÀÇ;µ¿½ÃÀÇ
  • real-time system
    ½Ç½Ã°£(Áï½Ãó¸®)½Ã½ºÅÛ(´Ü¸»¿¡¼­ º¸³»¿Â µ¥ÀÌÅ͸¦ Áï½Ã ÄÄÇ»ÅÍ¿¡ ó¸®ÇÏ¿© ´Ü¸»·Î µÇµ¹¸®´Â ½Ã½ºÅÛ)
  • released time
    ±³¿Ü Á¾±³ ±³À° µîÀ» À§ÇÑ ÀÚÀ¯ ½Ã°£
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á